Skip to main content

Table 6 Summary of dichotomous outcomes for tadalafil

From: Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction

  

Number of

Percent with

  

Outcome

Dose (mg)

Trials

Patients

Tadalafil

Placebo

Relative benefit or risk (95% CI)

NNT/NNTp/NNH(95% CI)

Efficacy

Improved erections

10

2

215

64

23

2.8 (1.9 to 4.2)

2.4 (1.9 to 3.4)

 

20

7

1542

76

24

3.1 (2.7 to 3.7)

1.9 (1.7 to 2.1)

 

10/20

7

1651

75

24

3.1 (2.6 to 3.7)

1.9 (1.8 to 2.1)

Withdrawal

All-cause

10/20

5

1334

13

19

0.7 (0.5 to 0.9)

15 (8.8 to 46)

Lack of efficacy

10/20

6

1435

3.3

7.5

0.5 (0.3 to 0.7)

24 (14 to 69)

Adverse event

10/20

7

1657

3.4

1.5

2.3 (1.1 to 5.1)

52 (29 to 260)

Adverse events

All cause

10/20

3

590

47

25

1.8 (1.4 to 2.3)

4.6 (3.4 to 7.2)

Serious

10/20

7

1655

1.2

1.1

1.0 (0.4 to 2.8)

not calculated

Headache

10/20

7

1810

13

3.4

3.5 (2.2 to 5.4)

11 (8.5 to 14)

Dyspepsia

10/20

6

1401

10

0.2

12 (4.3 to 35)

11 (8.8 to 14)

Flushing

10/20

6

1530

4.8

0.2

7.2 (2.5 to 20)

24 (18 to 38)

Rhinitis

10/20

2

712

3.1

0.5

4.5 (0.8 to 24)

not calculated

  1. NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us